Pharma Industrial India - Professional magazine for pharma industry suppliers and lab technology

NEWS ABOUT >

Biotechnology

Clean Rooms

Clinical Trials

Consultants

Digitalization

Drug Discovery & Development

Engineering

Global Pharma

Industrial talks

Ingredients

Lab Equipment

Logistics & Distribution

Manufacturing

Market

Outsourcing

Packaging

Quality / GMP

Regulation

Safety

Last edition

All magazines
Subscribe to our magazine

News about "IL-23 Inhibitor"

AbbVie Seeks EMA Approval for Subcutaneous SKYRIZI in Crohn's Disease

AbbVie submits an European Medicines Agency (EMA) application for subcutaneous SKYRIZI induction in adults with moderately to severely active Crohn’s Disease (CD), supported by phase 3 AFFIRM data.

IL-23 Inhibitor | 27/08/2026 | By News Bureau

US FDA Approves TREMFYA Label Update for Inhibition of Joint Damage Progression in Psoriatic Arthritis

Johnson & Johnson’s IL-23 inhibitor becomes the first in its class to include evidence of structural joint damage inhibition in adults with active psoriatic arthritis.

IL-23 Inhibitor | 30/05/2026 | By News Bureau | 128

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members